Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inoperable Locally Advanced HER2-Negative Breast Cancer × pembrolizumab × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡